Last reviewed · How we verify
JP-1366
At a glance
| Generic name | JP-1366 |
|---|---|
| Sponsor | Onconic Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban (PHASE1)
- Phase 1 Study of JLP-2302 and JP-1366: PK and Safety in Healthy Volunteers (PHASE1)
- Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease (PHASE3)
- A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis (PHASE3)
- Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers (PHASE3)
- JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis (PHASE3)
- Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer (PHASE3)
- Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |